Tekla Capital Management LLC Has $128.04 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Tekla Capital Management LLC lifted its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 51.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 783,779 shares of the company’s stock after purchasing an additional 267,127 shares during the quarter. Johnson & Johnson accounts for approximately 5.2% of Tekla Capital Management LLC’s holdings, making the stock its 2nd largest position. Tekla Capital Management LLC’s holdings in Johnson & Johnson were worth $128,038,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Johnson & Johnson by 18.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after buying an additional 3,912,430 shares during the period. Legal & General Group Plc lifted its holdings in shares of Johnson & Johnson by 2.3% in the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after buying an additional 421,779 shares during the period. FMR LLC lifted its holdings in shares of Johnson & Johnson by 20.8% in the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after buying an additional 3,229,032 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Johnson & Johnson by 1.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after purchasing an additional 328,297 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Johnson & Johnson by 0.3% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock valued at $1,333,545,000 after purchasing an additional 24,505 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $168.74 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock’s 50-day moving average is $176.14 and its two-hundred day moving average is $171.20. The firm has a market cap of $441.17 billion, a P/E ratio of 23.50, a PEG ratio of 3.19 and a beta of 0.56.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.68%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s payout ratio is currently 62.95%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on JNJ. Sanford C. Bernstein reduced their target price on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Bank of America reduced their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. SVB Leerink reduced their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday. Citigroup upped their target price on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Finally, Morgan Stanley reduced their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 6th. Seven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $181.75.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CAO Robert J. Decker sold 16,928 shares of the stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock valued at $40,960,735 in the last three months. Insiders own 0.35% of the company’s stock.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.